Concurrent chemoradiotherapy in squamous cell carcinoma of the anal canal: A tertiary care experience in North India

The aim of this study was to study the treatment outcome and survival of squamous cell carcinoma anal canal using concurrent chemoradiotherapy in a tertiary care hospital. This was a retrospective study performed in our hospital, in which all necessary clinical and epidemiological details of the 38 cases diagnosed with squamous cell carcinoma anal canal from January 2015 to December 2021 were analyzed. Most patients were male in gender, 22 (57.90%) and 16 (42.10%) were females, with a male: female ratio of (1.37:1). All patients received concurrent chemoradiation as the definitive treatment. The mean 5-year survivals were (48 months). Five years of overall survival was 68% and for clinical stage I, II, and III was 100%, 64%, and 37%, respectively. The standard of care for stage I to III anal squamous cell carcinoma is concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C with excellent response rates. (author)